A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition

Cell Stem Cell

Volumn 12, Issue 3, 2013, Pages 316-328

  Goff, Daniel J ^a   Recart, Angela Court ^a   Sadarangani, Anil ^a   Chun, Hye Jung ^d   Barrett, Christian L ^b   Krajewska, Maryla ^e   Leu, Heather ^a   Low Marchelli, Janine ^a   Ma, Wenxue ^a   Shih, Alice Y ^a   Wei, Jun ^e   Zhai, Dayong ^e   Geron, Ifat ^a   Pu, Minya ^a   Bao, Lei ^a   Chuang, Ryan ^a   Balaian, Larisa ^a   Gotlib, Jason ^f   Minden, Mark ^g   Martinelli, Giovanni ^h   Rusert, Jessica ^c   Dao, Kim Hien ⁱ   Shazand, Kamran ^j   Wentworth, Peggy ^a   Smith, Kristen M ^a   Jamieson, Christina A M ^a   Morris, Sheldon R ^a   Messer, Karen ^a   Goldstein, Lawrence S B ^c   Hudson, Thomas J ^j   Marra, Marco ^d   Frazer, Kelly A ^b   Pellecchia, Maurizio ^e   Reed, John C ^e   Jamieson, Catriona H M ^a   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e BURNHAM INSTITUTE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; SABUTOCLAX; UNCLASSIFIED DRUG;

ARTICLE; BLAST CELL CRISIS; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; STEM CELL; XENOTRANSPLANTATION;

BLAST CRISIS; GOSSYPOL; HUMANS; LEUKEMIA; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84875131206     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2012.12.011     Document Type: Article

References (71)

1. A. Abe, Y. Minami, F. Hayakawa, K. Kitamura, Y. Nomura, M. Murata, A. Katsumi, H. Kiyoi, C.H. Jamieson, J.Y. Wang, and T. Naoe Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy Int. J. Hematol. 88 2008 471 475
2. A.E. Abrahamsson, I. Geron, J. Gotlib, K.H. Dao, C.F. Barroga, I.G. Newton, F.J. Giles, J. Durocher, R.S. Creusot, and M. Karimi Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation Proc. Natl. Acad. Sci. USA 106 2009 3925 3929
3. K.J. Aichberger, M. Mayerhofer, M.T. Krauth, H. Skvara, S. Florian, K. Sonneck, C. Akgul, S. Derdak, W.F. Pickl, and V. Wacheck Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides Blood 105 2005 3303 3311
4. C. Akgul, D.A. Moulding, and S.W. Edwards Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications Cell. Mol. Life Sci. 61 2004 2189 2199
5. G.P. Amarante-Mendes, A.J. McGahon, W.K. Nishioka, D.E. Afar, O.N. Witte, and D.R. Green Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL Oncogene 16 1998 1383 1390
6. D.J. Barnes, and J.V. Melo Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia Cell Cycle 5 2006 2862 2866
7. L.J. Beverly, and H.E. Varmus MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family Oncogene 28 2009 1274 1279
8. N.N. Bewry, R.R. Nair, M.F. Emmons, D. Boulware, J. Pinilla-Ibarz, and L.A. Hazlehurst Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance Mol. Cancer Ther. 7 2008 3169 3175
9. C.D. Bingle, R.W. Craig, B.M. Swales, V. Singleton, P. Zhou, and M.K. Whyte Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death J. Biol. Chem. 275 2000 22136 22146
10. S. Chen, Y. Dai, H. Harada, P. Dent, and S. Grant Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation Cancer Res. 67 2007 782 791
11. J.C. Chomel, and A.G. Turhan Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy Oncotarget 2 2011 713 727
12. J.C. Chomel, M.L. Bonnet, N. Sorel, A. Bertrand, M.C. Meunier, S. Fichelson, M. Melkus, A. Bennaceur-Griscelli, F. Guilhot, and A.G. Turhan Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease Blood 118 2011 3657 3660
13. A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, and B.J. Druker Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity J. Clin. Invest. 121 2011 396 409
14. J. Cortes, S. O'Brien, and H. Kantarjian Discontinuation of imatinib therapy after achieving a molecular response Blood 104 2004 2204 2205
15. Y. Dai, M. Rahmani, S.J. Corey, P. Dent, and S. Grant A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 J. Biol. Chem. 279 2004 34227 34239
16. G.Q. Daley, R.A. Van Etten, and D. Baltimore Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 1990 824 830
17. M. Deininger Resistance and relapse with imatinib in CML: causes and consequences J. Natl. Compr. Canc. Netw. 6 Suppl 2 2008 S11 S21
18. Q. Ding, X. He, W. Xia, J.M. Hsu, C.T. Chen, L.Y. Li, D.F. Lee, J.Y. Yang, X. Xie, J.C. Liu, and M.C. Hung Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer Cancer Res. 67 2007 4564 4571
19. J. Domen, and I.L. Weissman Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2 Exp. Hematol. 31 2003 631 639
20. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C.L. Sawyers Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
21. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N. Engl. J. Med. 355 2006 2408 2417
22. K. Eppert, K. Takenaka, E.R. Lechman, L. Waldron, B. Nilsson, P. van Galen, K.H. Metzeler, A. Poeppl, V. Ling, and J. Beyene Stem cell gene expression programs influence clinical outcome in human leukemia Nat. Med. 17 2011 1086 1093
23. E.C. Forsberg, E. Passegué, S.S. Prohaska, A.J. Wagers, M. Koeva, J.M. Stuart, and I.L. Weissman Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells PLoS ONE 5 2010 e8785
24. F. Gesbert, and J.D. Griffin Bcr/Abl activates transcription of the Bcl-X gene through STAT5 Blood 96 2000 2269 2276
25. N. Goardon, E. Marchi, A. Atzberger, L. Quek, A. Schuh, S. Soneji, P. Woll, A. Mead, K.A. Alford, and R. Rout Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia Cancer Cell 19 2011 138 152
26. D.A. Goldman, and J.D. Brender Are standardized mortality ratios valid for public health data analysis? Stat. Med. 19 2000 1081 1088
27. M.L. Guzman, C.F. Swiderski, D.S. Howard, B.A. Grimes, R.M. Rossi, S.J. Szilvassy, and C.T. Jordan Preferential induction of apoptosis for primary human leukemic stem cells Proc. Natl. Acad. Sci. USA 99 2002 16220 16225
28. P.C. Hermann, S. Bhaskar, M. Cioffi, and C. Heeschen Cancer stem cells in solid tumors Semin. Cancer Biol. 20 2010 77 84
29. D.E. Hogge, P.M. Lansdorp, D. Reid, B. Gerhard, and C.J. Eaves Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor Blood 88 1996 3765 3773
30. T. Holyoake, X. Jiang, C. Eaves, and A. Eaves Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia Blood 94 1999 2056 2064
31. M. Horita, E.J. Andreu, A. Benito, C. Arbona, C. Sanz, I. Benet, F. Prosper, and J.L. Fernandez-Luna Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL J. Exp. Med. 191 2000 977 984
32. S. Jaiswal, D. Traver, T. Miyamoto, K. Akashi, E. Lagasse, and I.L. Weissman Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias Proc. Natl. Acad. Sci. USA 100 2003 10002 10007
33. C.H. Jamieson, L.E. Ailles, S.J. Dylla, M. Muijtjens, C. Jones, J.L. Zehnder, J. Gotlib, K. Li, M.G. Manz, and A. Keating Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N. Engl. J. Med. 351 2004 657 667
34. M. Karbasian Esfahani, E.L. Morris, J.P. Dutcher, and P.H. Wiernik Blastic phase of chronic myelogenous leukemia Curr. Treat. Options Oncol. 7 2006 189 199
35. M. Konopleva, S. Zhao, W. Hu, S. Jiang, V. Snell, D. Weidner, C.E. Jackson, X. Zhang, R. Champlin, and E. Estey The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells Br. J. Haematol. 118 2002 521 534
36. A.V. Krivtsov, D. Twomey, Z. Feng, M.C. Stubbs, Y. Wang, J. Faber, J.E. Levine, J. Wang, W.C. Hahn, and D.G. Gilliland Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9 Nature 442 2006 818 822
37. J. Kuroda, H. Puthalakath, M.S. Cragg, P.N. Kelly, P. Bouillet, D.C. Huang, S. Kimura, O.G. Ottmann, B.J. Druker, and A. Villunger Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic Proc. Natl. Acad. Sci. USA 103 2006 14907 14912
38. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
39. D.H. Mak, R.Y. Wang, W.D. Schober, M. Konopleva, J. Cortes, H. Kantarjian, M. Andreeff, and B.Z. Carter Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors Leukemia 26 2012 788 794
40. P.J. Martin, V. Najfeld, J.A. Hansen, G.K. Penfold, R.J. Jacobson, and P.J. Fialkow Involvement of the B-lymphoid system in chronic myelogenous leukaemia Nature 287 1980 49 50
41. S.K. McWeeney, L.C. Pemberton, M.M. Loriaux, K. Vartanian, S.G. Willis, G. Yochum, B. Wilmot, Y. Turpaz, R. Pillai, and B.J. Druker A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib Blood 115 2010 315 325
42. P. Mehlen, and A. Puisieux Metastasis: a question of life or death Nat. Rev. Cancer 6 2006 449 458
43. Y. Meng, Y. Li, J. Li, H. Li, J. Fu, Y. Liu, H. Liu, and X. Chen (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells Leuk. Lymphoma 48 2007 2204 2212
44. M. Milyavsky, O.I. Gan, M. Trottier, M. Komosa, O. Tabach, F. Notta, E. Lechman, K.G. Hermans, K. Eppert, and Z. Konovalova A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal Cell Stem Cell 7 2010 186 197
45. M.J. Moore, Q. Wang, C.J. Kennedy, and P.A. Silver An alternative splicing network links cell-cycle control to apoptosis Cell 142 2010 625 636
46. K.P. Ng, A.M. Hillmer, C.T. Chuah, W.C. Juan, T.K. Ko, A.S. Teo, P.N. Ariyaratne, N. Takahashi, K. Sawada, and Y. Fei A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer Nat. Med. 18 2012 521 528
47. M. Ninomiya, A. Abe, A. Katsumi, J. Xu, M. Ito, F. Arai, T. Suda, M. Ito, H. Kiyoi, T. Kinoshita, and T. Naoe Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice Leukemia 21 2007 136 142
48. L.A. O'Reilly, D.C. Huang, and A. Strasser The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry EMBO J. 15 1996 6979 6990
49. L.A. O'Reilly, A.W. Harris, and A. Strasser bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors Int. Immunol. 9 1997 1291 1301
50. L.A. O'Reilly, A.W. Harris, D.M. Tarlinton, L.M. Corcoran, and A. Strasser Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo J. Immunol. 159 1997 2301 2311
51. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, and P.J. Hajduk An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
52. W.J. Placzek, J. Wei, S. Kitada, D. Zhai, J.C. Reed, and M. Pellecchia A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy Cell Death Dis. 1 2010 e40
53. J.P. Radich, H. Dai, M. Mao, V. Oehler, J. Schelter, B. Druker, C. Sawyers, N. Shah, W. Stock, and C.L. Willman Gene expression changes associated with progression and response in chronic myeloid leukemia Proc. Natl. Acad. Sci. USA 103 2006 2794 2799
54. J.C. Reed Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood 111 2008 3322 3330
55. Y. Saito, N. Uchida, S. Tanaka, N. Suzuki, M. Tomizawa-Murasawa, A. Sone, Y. Najima, S. Takagi, Y. Aoki, and A. Wake Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML Nat. Biotechnol. 28 2010 275 280
56. I. Sánchez-García, and G. Grütz Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2 Proc. Natl. Acad. Sci. USA 92 1995 5287 5291
57. C.L. Sawyers, A. Hochhaus, E. Feldman, J.M. Goldman, C.B. Miller, O.G. Ottmann, C.A. Schiffer, M. Talpaz, F. Guilhot, and M.W. Deininger Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 2002 3530 3539
58. C.I. Slape, J. Saw, J.B. Jowett, P.D. Aplan, A. Strasser, S.M. Jane, and D.J. Curtis Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome Blood 120 2012 2475 2483
59. S.A. Stuart, Y. Minami, and J.Y. Wang The CML stem cell: evolution of the progenitor Cell Cycle 8 2009 1338 1343
60. T. Tauchi, M. Sumi, A. Nakajima, G. Sashida, T. Shimamoto, and K. Ohyashiki BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells Clin Cancer Res. 9 2003 4267 4273
61. G. Vairo, K.M. Innes, and J.M. Adams Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival Oncogene 13 1996 1511 1519
62. J.E. Visvader Cells of origin in cancer Nature 469 2011 314 322
63. M. Vogler, M. Butterworth, A. Majid, R.J. Walewska, X.M. Sun, M.J. Dyer, and G.M. Cohen Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia Blood 113 2009 4403 4413
64. M. Vogler, D. Dinsdale, M.J. Dyer, and G.M. Cohen Bcl-2 inhibitors: small molecules with a big impact on cancer therapy Cell Death Differ. 16 2009 360 367
65. J. Wei, S. Kitada, M.F. Rega, J.L. Stebbins, D. Zhai, J. Cellitti, H. Yuan, A. Emdadi, R. Dahl, and Z. Zhang Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins J. Med. Chem. 52 2009 4511 4523
66. J. Wei, J.L. Stebbins, S. Kitada, R. Dash, W. Placzek, M.F. Rega, B. Wu, J. Cellitti, D. Zhai, and L. Yang BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins J. Med. Chem. 53 2010 4166 4176
67. D. Yecies, N.E. Carlson, J. Deng, and A. Letai Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1 Blood 115 2010 3304 3313
68. K. Yoshida, M. Sanada, Y. Shiraishi, D. Nowak, Y. Nagata, R. Yamamoto, Y. Sato, A. Sato-Otsubo, A. Kon, and M. Nagasaki Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
69. C. Zhao, J. Blum, A. Chen, H.Y. Kwon, S.H. Jung, J.M. Cook, A. Lagoo, and T. Reya Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo Cancer Cell 12 2007 528 541
70. C. Zhao, A. Chen, C.H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H.Y. Kwon, J. Kim, J.P. Chute, and D. Rizzieri Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia Nature 458 2009 776 779
71. S. Zinkel, A. Gross, and E. Yang BCL2 family in DNA damage and cell cycle control Cell Death Differ. 13 2006 1351 1359